AXDX News Accelerate Diagnostics Inc 21.86 $AXDX

AXDX News Accelerate Diagnostics Inc 21.86 $AXDX

Allegiance Bancshares, Inc. to Participate in the Piper Jaffray Bank Symposium
GlobeNewswire - Fri Dec 11, 4:05PM CST
Allegiance Bancshares, Inc. (NASDAQ:ABTX), the holding company of Allegiance Bank (collectively, "Allegiance" , today announced that its management team will participate in the Piper Jaffray Bank Symposium to be held in Palm Beach, Florida on December 14, 2015. The presentation used in the investor meetings will be available in the Investor Relations section of Allegiance's website at www.allegiancebank.com on December 14, 2015.
ABTX: 23.25 (-0.90)

Newly Listed Allegiance Bancshares, Inc. Rings NASDAQ Closing Bell
GlobeNewswire - Thu Nov 12, 12:50PM CST
Allegiance Bancshares, Inc. (NASDAQ:ABTX), the holding company of Allegiance Bank (collectively, "Allegiance" , celebrated its recent listing by ringing the closing bell at the NASDAQ MarketSite in Times Square, in New York City on Friday, November 6, 2015.
ABTX: 23.25 (-0.90)

Allegiance Bancshares, Inc. (Nasdaq:ABTX) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Nov 05, 9:00AM CST
What:
ABTX: 23.25 (-0.90), NDAQ: 55.67 (+0.81)

Allegiance Bancshares, Inc. Reports Solid Third Quarter 2015 Earnings
GlobeNewswire - Fri Oct 30, 4:20PM CDT
-- Diluted earnings per common share of $0.40 for the third quarter 2015 compared to $0.36 for the second quarter 2015
ABTX: 23.25 (-0.90)

Allegiance Bancshares, Inc. Announces Third Quarter 2015 Earnings Call and Conference Call Schedule
GlobeNewswire - Tue Oct 20, 11:54AM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance" , the holding company of Allegiance Bank, today announced that it will hold a conference call to discuss its third quarter results on Monday, November 2, 2015 at 9:00 a.m. Central (10:00 a.m. Eastern). The conference call will be hosted by George Martinez, Chairman and CEO, Steve Retzloff, President, and Larry Lehman, Executive Vice President and CFO. The related earnings release will be issued following the close of the market on Friday, October 30, 2015 and will also be available on the Investor Relations section of the website at www.allegiancebank.com, under Financial Information.
ABTX: 23.25 (-0.90)

Allegiance Bancshares, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Wed Oct 14, 12:30PM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance" , the holding company of Allegiance Bank, a Texas state chartered bank, announced today that it has completed the previously announced initial public offering of 2,990,000 shares of its common stock to the public at $21.00 per share for gross proceeds of approximately $62.8 million (including 390,000 shares subject to the underwriters' over-allotment option, which was exercised in full on October 9, 2015). Allegiance's common stock began trading on the NASDAQ Global Market on October 8, under the ticker symbol "ABTX."
ABTX: 23.25 (-0.90)

Allegiance Bancshares, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Oct 07, 7:44PM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance" , the holding company of Allegiance Bank, a Texas state chartered bank, announced today the pricing of its initial public offering of 2,600,000 shares of common stock at $21.00 per share for gross proceeds of approximately $54.6 million. Shares are expected to begin trading tomorrow, October 8, 2015, on the NASDAQ Global Market under the ticker symbol "ABTX."
ABTX: 23.25 (-0.90)

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - 10 mins ago
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 7.68 (+0.57), NRX: 2.23 (+0.79), AKBA: 10.96 (+1.21), BSI: 3.60 (+3.26)

Akebia Secures Asian Partner and Funding for Anemia Pill
at The Street - Mon Dec 14, 6:01AM CST
Mitsubishi will pay Akebia $40 million upfront to license vadadustat for the Asian market. The Japanese drug maker will also contribute another $60 million towards Akebia'a global phase III program.
FGEN: 29.22 (+0.35), AKBA: 10.96 (+1.21)

Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
Business Wire - Mon Dec 14, 6:00AM CST
--- Akebia to Host Conference Call at 8:30 AM Eastern Time Today -
AKBA: 10.96 (+1.21)

Akebia Therapeutics reports 3Q loss
Automated Insights - Mon Nov 09, 6:35AM CST
CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Monday reported a loss of $19.5 million in its third quarter.
AKBA: 10.96 (+1.21)

Akebia Announces Third Quarter 2015 Financial Results
GlobeNewswire - Mon Nov 09, 6:00AM CST
-Positive Phase 2 data of vadadustat in Dialysis Dependent Chronic Kidney Disease (CKD) Patients Presented at American Society of Nephrology (ASN) Kidney Week-
AKBA: 10.96 (+1.21)

Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting
GlobeNewswire - Sat Nov 07, 2:00PM CST
- Vadadustat Maintained Stable Hemoglobin Levels in All Three Dose Cohorts Following Conversion from rESA Therapy -
AKBA: 10.96 (+1.21)

Global Colitis Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/tg9gvp/colitis) has announced the addition of the "Colitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akebia Therapeutics, Inc. - Amorepacific Corporation - Bayer AG - Dr. Falk Pharma GmbH - Galapagos NV - GeneFrontier Corporation - Innate Pharma SA - Nivalis Therapeutics, Inc. - Peptinov SAS - Prokarium Limited - Protalix BioTherapeutics, Inc. - RDD Pharma Ltd. - Saniona AB - Synovo GmbH For more information visit http://www.researchandmarkets.com/research/tg9gvp/colitis
NVLS: 7.93 (-0.03), AKBA: 10.96 (+1.21), GLPG: 57.15 (-0.38)

UPDATE: Akebia to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Thu Nov 05, 4:37PM CST
In a release issued previously by Akebia Therapeutics, Inc. (NASDAQ:AKBA), the company is updating the presentation time to 3:00 p.m. Mountain Time instead of 3:30 p.m. Mountain Time. The updated release follows:
AKBA: 10.96 (+1.21)

Akebia to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Tue Nov 03, 4:48PM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Jason A. Amello, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10, 2015 at 3:30 p.m. Mountain Time. The conference will take place at The Phoenician resort, in Scottsdale, Arizona.
AKBA: 10.96 (+1.21)

Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting
GlobeNewswire - Wed Oct 28, 3:53PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the vadadustat (formerly AKB-6548) development program will be presented at the upcoming American Society of Nephrology (ASN) Kidney Week 2015 annual meeting in San Diego, California from November 3-8, 2015.
AKBA: 10.96 (+1.21)

INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Akebia Therapeutics, Inc. on Behalf of Investors
Business Wire - Tue Oct 13, 8:09PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Akebia Therapeutics, Inc. ("Akebia" or the "Company" (AKBA). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
AKBA: 10.96 (+1.21)

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akebia Therapeutics, Inc. - AKBA
Business Wire - Thu Oct 08, 10:28AM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) resulting from allegations that Akebia Therapeutics may have issued materially misleading business information to the investing public.
AKBA: 10.96 (+1.21)

Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program
Business Wire - Tue Oct 06, 7:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA) and the Scientific Advice Process with the European Medicines Agency (EMA) for its lead product, vadadustat (formerly AKB-6548), for patients with anemia related to non-dialysis dependent chronic kidney disease (NDD-CKD). The company has reached agreement with both the FDA and EMA regarding key elements of the Phase 3 program, known as the PRO2TECT(TM) program, and expects to launch the program later this year.
AKBA: 10.96 (+1.21)

Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead
at The Street - Fri Oct 02, 5:09AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ARWR: 5.59 (-0.05), AZN: 32.81 (-0.44), AMGN: 155.55 (+0.40), FGEN: 29.22 (+0.35), AKBA: 10.96 (+1.21), CUR: 1.03 (+0.01)

Market Update on the Healthcare Sector - Amedica, Accuray, Acadia Healthcare, ANI Pharmaceuticals, and Akebia Therapeutics
PR Newswire - Mon Sep 28, 7:33AM CDT
ACI Association has initiated research coverage on the following equities: Amedica Corporation (NASDAQ: AMDA), Accuray Incorporated (NASDAQ: ARAY), Acadia Healthcare Company, Inc. (NASDAQ: ACHC), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Akebia Therapeutics, Inc. (NASDAQ: AKBA). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
ACHC: 62.90 (-0.26), ANIP: 41.67 (-0.94), AKBA: 10.96 (+1.21), ARAY: 6.36 (-0.01), AMDA: 0.13 (-0.02)

Biotech Poised to Rebound: 5 Growth Picks
Swarup Gupta - Zacks Investment Research - Tue Sep 15, 10:36AM CDT
The NASDAQ Biotechnology Index has already embarked upon a recovery this month, increasing 3.3%, and is poised for further gains.
RGEN: 27.64 (-0.46), ZSPH: 89.84 (unch), CLVS: 31.89 (-0.06), GILD: 99.96 (-0.07), VTAE: 14.20 (-0.59), VVUS: 0.97 (-0.03), AKBA: 10.96 (+1.21), BMY: 67.92 (+0.30), AFFX: 9.19 (+0.05), REGN: 534.98 (+0.47)

Akebia (AKBA) Skyrockets on Encouraging Phase II Data
Zacks Equity Research - Zacks Investment Research - Thu Sep 10, 3:35PM CDT
Akebia Therapeutics, Inc. (AKBA) announced positive top-line data from a phase II study on its lead candidate, vadadustat, in dialysis patients with anemia related to chronic kidney disease.
VRX: 93.74 (+0.68), AKBA: 10.96 (+1.21), INFI: 7.41 (+0.11), AMAG: 26.08 (-0.69)

Akebia to Present at the 2015 Morgan Stanley Global Healthcare Conference
Business Wire - Thu Sep 10, 3:30PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18,2015 at 10:30 a.m. Eastern Time. The conference will take place at the Grand Hyatt in New York City.
AKBA: 10.96 (+1.21), MS: 31.89 (-0.19)

Akebia Therapeutics Announces Additions to its Management Team
Business Wire - Thu Sep 10, 3:05PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced three additions to its senior management team: Teresa Compton, PhD joined Akebia as Senior Vice President and Chief Scientific Officer, Ramin Farzaneh-Far, MD as Vice President of Medical Research, and Ed Joyce as Vice President, Investor Relations and Corporate Communications.
GMED: 26.65 (+0.35), ROG: 51.06 (-0.31), AKBA: 10.96 (+1.21)

Why Akebia Therapeutics' Shares Are Soaring 53% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Sep 09, 1:19PM CDT
Akebia Therapeutics President & CEO John Butler presenting at the American Kidney Fund What: After reporting positive phase 2 trial results for its anemia drug, shares in Akebia Therapeutics jumped by 53% earlier today. So what: ...
AKBA: 10.96 (+1.21)

Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - 1 hr 11 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 187.79 (-4.18), CBIO: 2.14 (-0.13), ALXN: 190.21 (+2.15), GSK: 38.96 (-0.35), NVS: 84.73 (+0.21)

Apple Gets Bullish Call; GoPro Downgraded, Adobe Hiked
at Investor's Business Daily - Fri Dec 11, 3:57PM CST
Apple (AAPL) was started with a bullish analyst rating Friday, while GoPro (GPRO) was downgraded and Adobe Systems (ADBE) got a series of price target hikes. BMO Capital initiated coverage on Apple with an outperform rating. Earlier this week, Piper...
GPRO: 16.69 (-2.46), ALXN: 190.21 (+2.15), STZ: 137.57 (-0.73), HPQ: 12.18 (-0.03), AAPL: 111.23 (-1.95), CVC: 30.02 (-0.12), HPE: 14.25 (+0.07), ADBE: 91.29 (-0.13)

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/zkbpps/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Actelion Ltd - Adienne Pharma & Biotech - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Cancer Treatment International Limited - Biogen, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Cell2B S.A. - CytoDyn Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - GlaxoSmithKline Plc - ImmuNext, Inc. - Immunomedics, Inc. - Jazz Pharmaceuticals Plc - Kadmon Corporation, LLC - Kamada Ltd. - Kiadis Pharma B.V. - Kymab Limited - Neopharm Ltd. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmicell Co., Ltd. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Rigel Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Spherium Biomed S.L. - Therapix Biosciences Ltd - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/zk...ersus_host
IMMU: 2.99 (unch), BMY: 67.97 (+0.35), GSK: 38.96 (-0.35), RIGL: 3.24 (+0.08), CLBS: 1.08 (+0.02), BLCM: 18.08 (-0.25), SGEN: 39.94 (-0.63), JAZZ: 133.19 (-1.07), ALXN: 190.21 (+2.15), KMDA: 4.09 (-0.14), ABBV: 54.19 (+0.15), ATHX: 1.01 (-0.01), NVS: 84.73 (+0.21)

How Gilead's Dividend Can Inject Cash and Growth in Your Portfolio
at The Street - Fri Dec 11, 6:06AM CST
Beyond its dividend, Gilead Sciences projects healthy stock gains in the quarters ahead.
BIIB: 280.43 (-3.03), GILD: 100.11 (+0.08), XBI: 65.53 (-0.20), ALXN: 190.21 (+2.15)

Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting
Business Wire - Thu Dec 10, 4:00PM CST
--- Interim Phase 2 Data of ALXN1007 Show 28-Day Overall Acute Response Rate in Patients with GI-GVHD -
ALXN: 190.21 (+2.15)

Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting
Business Wire - Thu Dec 10, 5:37AM CST
--- Interim Phase 2 Data of ALXN1007 in Patients with GI-GVHD to be Presented -
ALXN: 190.21 (+2.15)

Alexion (ALXN) Gains after Kanuma Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 2:35PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA has cleared its enzyme replacement therapy, Kanuma.
ALXN: 190.21 (+2.15), BXLT: 37.97 (+0.93), ANIK: 37.21 (+0.21)

Pharmerging Markets 2016-2020
M2 - Wed Dec 09, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mhxgh/pharmerging) has announced the addition of the "Pharmerging Markets 2016-2020" report to their offering. This new report predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases. The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Global pharmaceuticals market PART 06: Pharmerging markets PART 07: Market landscape PART 08: Market segmentation based on geography PART 09: Market overview of Tier I countries PART 10: Market overview of Tier II countries PART 11: Market overview of Tier III countries PART 12: Market drivers PART 13: Impact of drivers PART 14: Market challenges PART 15: Impact of drivers and challenges PART 16: Market trends PART 17: Vendor landscape 20 of 45 Companies Mentioned: - AstraZeneca - GlaxoSmithKline - Merck - Novartis - Pfizer - Sanofi - Abbott Laboratories - AbbVie - Alexion Pharmaceuticals - Allergan - Amgen - Aspen - Astellas Pharma - Baxter - Bayer - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/9m...harmerging
AGN: 301.58 (-0.49), ABT: 44.45 (+0.09), MRK: 52.02 (-0.13), ALXN: 190.21 (+2.15), AMGN: 155.54 (+0.39), GSK: 38.96 (-0.35), BMY: 67.96 (+0.34), NVS: 84.73 (+0.21), CELGZ: 1.00 (-0.09)

Alexion Pharmaceuticals
at Investor's Business Daily - Tue Dec 08, 5:53PM CST
Alexion Pharmaceuticals (ALXN) won FDA approval for rare-disease drug Kanuma, representing its third-ever drug approval. The FDA approved Kanuma for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious organ damage and...
ALXN: 190.21 (+2.15)

Instant Analysis: Alexion Pharmaceuticals Inc Wins an Important FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Tue Dec 08, 3:22PM CST
What happened?  Rare disease focused A lexion Pharmaceuticals   shared good news today that Kanuma, its treatment for lysosomal acid lipase deficiency -- or LAL-D -- won FDA approval.  LAL-D is an awful, ultra-rare genetic metabolic disease in...
ALXN: 190.21 (+2.15)

Alexion Wins Third Drug Approval; Stock Rises
at Investor's Business Daily - Tue Dec 08, 1:18PM CST
Big-cap biotech Alexion Pharmaceuticals (ALXN) won FDA approval Tuesday for rare-disease drug Kanuma, representing its third-ever drug approval. Kanuma was approved for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious...
ALXN: 190.21 (+2.15)

ADDING MULTIMEDIA FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Business Wire - Tue Dec 08, 11:52AM CST
--- Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET -
ALXN: 190.21 (+2.15)

FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Business Wire - Tue Dec 08, 10:52AM CST
--- Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET -
ALXN: 190.21 (+2.15)

How it All Plays Out - Research on LinkedIn, Micron Technology, Alexion Pharmaceuticals and Fitbit
ACCESSWIRE - Tue Dec 08, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 8, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LinkedIn Corp. (NYSE: LNKD), Micron Technology Inc. (NASDAQ: MU), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) and Fitbit Inc. (NYSE: FIT). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FIT: 28.98 (-0.52), MU: 13.72 (-0.32), LNKD: 230.29 (-0.32), ALXN: 190.21 (+2.15)

Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.93%
Comtex SmarTrend(R) - Mon Dec 07, 4:35PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $176.63 to a high of $183.25. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $179.84 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 190.21 (+2.15)

Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscore Devastating Nature of PNH and Benefits of Soliris(R) (eculizumab) Treatment
Business Wire - Mon Dec 07, 3:05PM CST
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that researchers presented data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry that advance the understanding of PNH and provide important information for the medical community on the long-term management of the disease, including the progression of symptoms in untreated patients with PNH and the continued benefits of ongoing Soliris(R) (eculizumab) treatment regardless of transfusion history. Researchers also presented data from a long-term follow-up study evaluating the effectiveness of Soliris in preventing thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are severe, ultra-rare diseases caused by chronic uncontrolled complement activation. These data were presented at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando.
ALXN: 190.21 (+2.15)

Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 190.21 (+2.15), IBIO: 0.58 (+0.03), FOLD: 9.32 (-0.09)

Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 2.05% Yesterday
Comtex SmarTrend(R) - Wed Dec 02, 6:30PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $175.83 to a high of $179.84. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $177.57 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 190.21 (+2.15)

Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved
Arpita Dutt - Zacks Investment Research - Wed Dec 02, 1:09PM CST
Repros (RPRX) leads the headlines in a relatively slow Thanksgiving week with the FDA issuing a CRL for the company's experimental secondary hypogonadism treatment.
BIIB: 280.43 (-3.03), GILD: 100.11 (+0.08), ALXN: 190.21 (+2.15), RPRX: 1.24 (+0.02), AMGN: 155.54 (+0.39), ABBV: 54.19 (+0.15), XOMA: 1.27 (unch)

5 Health Care Trades to Buy for December Breakouts
at The Street - Tue Dec 01, 10:15AM CST
To make the most of a bullish turn in momentum in health care stocks, here is a technical look at five stocks to trade for gains.
SHPG: 187.79 (-4.18), ALXN: 190.21 (+2.15), AGIO: 51.46 (-2.28), LLY: 83.74 (+0.45), XRAY: 59.75 (-0.04)

Atmel (ATML) Stock Surges on New Takeover Offer
at The Street - 32 mins ago
Atmel (ATML) stock is rising in early-morning trading on Monday, after the company received a takeover offer of $9 in cash per share.
ATML: 8.78 (+0.32)

Embedded Systems Global Strategic Business Report - Analysis, Trends, Technologies & Forecast 2015-2020
M2 - 2 hrs 57 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n727dv/embedded_systems) has announced the addition of the "Embedded Systems - Global Strategic Business Report" report to their offering. This comprehensive report provides a detailed understanding of the global Embedded Systems market and the various factors predicted to affect this market in the coming years. It considers current and future drivers, challenges and opportunities, resulting in an unrivalled analysis of this market and the confidence needed to make informed business decisions in this market. Data is provided on a global and regional level and the following End-Use Segments: - Computing - Telecommunications - Consumer Electronics - Others The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also included is a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 57 companies including many key and niche players including: - Altera Corporation - ARM Limited - Atmel Corporation - Axiomtek - Freescale Semiconductor, Inc. Report Structure: EMBEDDED SYSTEMS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET TRENDS & DRIVERS 3. PRODUCT OVERVIEW 4. PRODUCT INTRODUCTIONS/INNOVATIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/n7...ed_systems
ATML: 8.78 (+0.32), ALTR: 53.03 (+0.04)

Atmel announces receipt of unsolicited proposal to acquire all outstanding shares of common stock
M2 - Mon Dec 14, 6:28AM CST
Atmel Corporation (Nasdaq:ATML), a provider of microcontroller and touch solutions, announced on Friday that it has received an unsolicited proposal to acquire all of the outstanding shares of Atmel common stock.
ATML: 8.78 (+0.32)

European Stocks Rise as Eurozone Production Jumps
at The Street - Mon Dec 14, 5:23AM CST
European stocks rise on Monday amid a better-than-expected rise in euro-area industrial production and optimism about rate action from the U.S. this week.
ATML: 8.78 (+0.32), RDS.A: 43.57 (-0.97), AZN: 32.85 (-0.40)

Dialog Semiconductor's announces submission of registration statement to US SEC and acknowledges Atmel's receipt of its unsolicited acquisition proposal
M2 - Mon Dec 14, 5:08AM CST
Dialog Semiconductor plc (Xetra LG) announced on Friday, that consistent with its status as a foreign private issuer, it has confidentially submitted a draft registration statement on Form F-4 with the US Securities and Exchange Commission in connection with its proposed acquisition of Atmel Corporation (Nasdaq: ATML).
ATML: 8.78 (+0.32)

Dialog Semiconductor Plc.: Dialog Semiconductor Announces Submission of Registration Statement and Acknowledges Atmel's Receipt of Unsolicited Proposal
Business Wire - Fri Dec 11, 9:15PM CST
Dialog Semiconductor plc ("Dialog" or "Company" (XETRA: DLG) today announced that, consistent with its status as a foreign private issuer, it has confidentially submitted a draft registration statement on Form F-4 with the United States Securities and Exchange Commission (the "SEC" in connection with its previously announced proposed acquisition of Atmel Corporation (Nasdaq: ATML). The registration statement contains a draft prospectus and proxy statement in connection with the proposed acquisition. The definitive versions of the prospectus and proxy statement will be filed publicly with the SEC and mailed to stockholders of Atmel prior to the time the Atmel shareholder meeting is scheduled.
ATML: 8.78 (+0.32)

Atmel Acknowledges Receipt of Unsolicited Proposal
PR Newswire - Fri Dec 11, 5:00PM CST
Atmel® Corporation (Nasdaq: ATML), a leader in microcontroller and touch solutions, today announced that it has received an unsolicited proposal to acquire all of the outstanding shares of Atmel common stock. Under the terms of the proposal, Atmel stockholders would receive $9.00 in cash per share, with the option to receive, in lieu of cash, shares of the acquiror in an amount of up to $1.0 billion in aggregate value, based on a ten-day trailing average of the acquiror's closing stock price measured as of transaction close.
ATML: 8.78 (+0.32)

Atmel (ATML) Shows Promise with Healthy Organic Growth
Zacks Equity Research - Zacks Investment Research - Mon Dec 07, 10:50AM CST
On Dec 7, Zacks Investment Research updated the research report on leading microcontroller and touch solutions provider Atmel Corporation (ATML).
ATML: 8.78 (+0.32), ANAD: 0.37 (unch), FORM: 8.42 (-0.09), AMCC: 6.46 (-0.12)

BUYINS.NET: ATML SqueezeTrigger Price is $8.24. There is $109,030,032 That Short Sellers Still Need To Cover.
M2 - Wed Dec 02, 10:30PM CST
November 18, 2015
ATML: 8.78 (+0.32)

Avnet Celebrates Silver Anniversary in the Americas with Atmel
M2 - Wed Dec 02, 9:20PM CST
November 19, 2015
ATML: 8.78 (+0.32), AVT: 43.78 (-0.54)

Atmel Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Fri Nov 27, 5:38PM CST
Atmel (NASDAQ:ATML) traded in a range yesterday that spanned from a low of $8.52 to a high of $8.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $8.53 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ATML: 8.78 (+0.32)

Atmel Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 24, 5:09PM CST
Atmel (NASDAQ:ATML) traded in a range yesterday that spanned from a low of $8.30 to a high of $8.44. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $8.39 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ATML: 8.78 (+0.32)

Atmel (ATML) Stock Rallies, Dialog Stockholders Support $4.6 Billion Deal
at The Street - Thu Nov 19, 10:55AM CST
Atmel (ATML) shares are higher on Thursday after Dialog Semiconductor shareholders approved the company's $4.6 billion takeover of Atmel.
ATML: 8.78 (+0.32)

Exosite Launches New Partner Program - Exosite IoT Alliance
Business Wire - Thu Nov 19, 9:00AM CST
Exosite (www.exosite.com), whose enterprise-grade cloud platform accelerates the time-to-market for IoT solutions, announced the Exosite IoT Alliance, a collaboration of edge devices, communication, business systems and software, and solution providers. The Exosite IoT Alliance is an ecosystem of like-minded companies and technology providers focused on advancing innovation in the digital enterprise and accelerating the overall adoption of IoT.
ATML: 8.78 (+0.32), MCHP: 44.41 (-0.23)

Dialog Semiconductor Announces Resolution in respect of the ATMEL Acquisition has been Passed at the General Meeting
Business Wire - Thu Nov 19, 7:45AM CST
Dialog Semiconductor plc (XETRA LG) today announced that at an extraordinary general meeting of shareholders held today, the Dialog shareholders have approved the allocation of shares required to complete the company's previously announced acquisition of Atmel Corporation (NASDAQ: ATML). The resolution was approved by a vote of 61.94% of the shares represented at the meeting.
ATML: 8.78 (+0.32)

Shareholder Resolution in Favor of the Acquisition of Atmel Has Been Passed at the General Meeting of Dialog Semiconductor
Business Wire - Thu Nov 19, 7:45AM CST
On 20 September 2015, Dialog Semiconductor Plc (XTRA: DLG) ("Dialog" announced that it had entered into a merger agreement pursuant to which it will acquire Atmel Corporation (NASDAQ: ATML). The acquisition is subject to a resolution by Dialog's shareholders granting authority to the board of directors of Dialog to issue and allot new shares in Dialog (the "Resolution" . At today's General Meeting of Dialog, the Resolution has been passed. The total number of shares in issue as at 12.00 noon GMT (1.00 p.m. CET) on 17 November 2015 was 77,865,955 shares. The total number of votes cast was 42,312,471 or 54.34% of the issued share capital. The result of the poll was 26,209,631 or 61.94% votes "For", 16,102,840 or 38.06% votes "Against".
ATML: 8.78 (+0.32)

Antares Pharma Announces FDA Approval of Sumatriptan Injection USP
GlobeNewswire - 1 hr 42 mins ago
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for 4 mg/0.5 mL and 6 mg/0.5 mL Sumatriptan Injection USP in adults for the acute treatment of migraine and cluster headache when a clear diagnosis has been established. The reference listed drug in the ANDA was GlaxoSmithKline's ImitrexInjection. Sumatriptan Injection USP represents the Company's first ANDA approval of a complex generic and second product approved using the VIBEX auto injector platform. In accordance with our previously disclosed agreement, Teva Pharmaceutical Industries, Ltd. (Teva) will distribute the product through their U.S. generic division and share the profits equally with Antares Pharma.
TEVA: 64.66 (+0.17), GSK: 38.92 (-0.39), ATRS: 1.29 (+0.03)

5 Stocks Under $10 Set to Soar
at The Street - Sun Dec 06, 2:45PM CST
These under-$10 stocks are within range of triggering breakout trades and moving much higher from current levels.
ROKA: 1.20 (unch), ENPH: 2.07 (-0.03), THST: 1.12 (-0.03), RUN: 8.25 (+0.39), ASTI: 0.15 (-0.02), LLEX: 0.20 (-0.01), CSLT: 4.00 (+0.12), BSI: 3.60 (+3.26), ATRS: 1.29 (+0.03)

Antares Pharma to Present at the 26th Annual Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 02, 6:00AM CST
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 26 Annual Oppenheimer Healthcare Conference on Wednesday, December 9, 2015 at 10:55 a.m. Eastern Time.
ATRS: 1.29 (+0.03)

Antares Pharma Announces Poster Presentation at the Sexual Medicine Society Scientific Annual Meeting
GlobeNewswire - Fri Nov 20, 6:00AM CST
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate delivered through the QuickShot auto injector was selected for a moderated poster presentation on November 21, 2015 at the 21 Annual Fall Scientific Meeting of the Sexual Medicine Society of North America.
ATRS: 1.29 (+0.03)

Antares Pharma Announces Podium Presentation of OTREXUP(TM) Dose Conversion Data at American College of Rheumatology Annual Meeting
GlobeNewswire - Mon Nov 09, 6:00AM CST
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that data derived from its Phase 2 study of the pharmacokinetics of subcutaneous versus oral methotrexate in the treatment of rheumatoid arthritis, was selected for a live, oral presentation on November 10, 2015 at the Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy Strategies session to be held during the 2015 Annual Meeting of the American College of Rheumatology, November 7 - 11 in San Francisco. The abstract, entitled "Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis," authored by Michael H. Schiff, MD et al., was among a select group of key abstracts awarded the distinction of a live, oral presentation.
ATRS: 1.29 (+0.03)

Antares Pharma reports 3Q loss
Automated Insights - Thu Nov 05, 9:07AM CST
EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Thursday reported a loss of $5.7 million in its third quarter.
ATRS: 1.29 (+0.03)

Antares Pharma Reports Third Quarter 2015 Operating and Financial Results
GlobeNewswire - Thu Nov 05, 6:01AM CST
Record Product Revenues Driven by Otrexup(TM) and Epinephrine Auto Injector Device Sales
ATRS: 1.29 (+0.03)

US Transdermal Patch Market & Clinical Trial Insight 2015 - 55 Patches in Clinical Pipeline, 27 Patches in Preclinical Phase & 33 US Patches
M2 - Wed Nov 04, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/s86v7x/us_transdermal) has announced the addition of the "US Transdermal Patch Market & Clinical Trial Insight" report to their offering. Innovations in pharmaceutical industry have a long track record of showing commercialization potential with respect to emerging and feasible technology. In US, such innovations have high level of acceptance among various stake holders of the pharmaceutical industry. Transdermal patches have emerged as one such innovations which have rich history but main development has been observed in past decade. They have been improved from a mere piece of tape dipped in formulation to complex matrix system containing therapeutics offering higher control over drug delivery. Long-term usage, high cost-effectiveness, high compliance rates and easy availability are some of the major factors behind the growth of transdermal patches in US. Consumer base for transdermal patches is quite high in US in comparison to other markets across the globe. Segments like female contraceptives and Nicotine Replacement Therapy (NRT) have received lots of attention in past years. Indications like Parkinson's disease and Alzheimer's disease have few transdermal patches and have unexplored opportunities in US market. While Insulin and vaccine patches are at different stages of clinical trials which would be introduced in coming years. Unexplored disease segments have less competition and lack of transdermal patches makes them suitable choice for potential transdermal patch developers. This scenario suggests that US transdermal patch market has lots of commercialization opportunities that have to be reaped in coming years. Some of the transdermal patches have completed their product life cycle and have given way to generic transdermal patches. Several small/mid-sized transdermal patch developers can take benefit of this scenario. Side-by-side, transdermal manufacturers have developed capabilities to customize products according to client's necessities. Improvement of transdermal patch technology is also expected to place as material science and associated fields are also developing. These observations suggest that US transdermal patch market will offer several commercialization opportunities. In this way, US transdermal patch segment shows progress at every level reflecting that this segment is expected to grow several folds in coming years. Key Topics Covered: 1. Introduction to Transdermal Patch 2. Types of Transdermal Patches 3. Mechanism of Transdermal Patch Drug Delivery 4. Advantages of Transdermal Patch 5. US Transdermal Patch Market Overview 6. Generic & Branded Transdermal Patches 7. US Transdermal Patch Market: Value Chain Analysis 8. US Transdermal Patch Contract Manufacturing Organization (CMO) 9. US Transdermal Patch Market Growth Frontiers 10. US Transdermal Patch Market Landscape 11. US Transdermal Patch Market Future Prospects 12. US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase 13. Marketed Transdermal Patch Clinical Insight by Company & Indication 14. Discontinued & Suspended Transdermal Patch Clinical Insight by Company, Indication & Phase 15. Competitive Landscape - 3M Pharmaceuticals - Acrux - Agile Therapeutics - Allergan - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Chase Pharmaceuticals - Corium International - DURECT Corporation - Endo Pharmaceuticals - Fempharm - Hisamitsu Pharmaceutical - Immune Pharmaceuticals - Imprimis Pharmaceuticals - Ipsen Bioscience - Johnson & Johnson - LaSalle Laboratories - Lavipharm-increase - MINRAD International - NeurogesX - Novartis - Noven Pharmaceuticals - NuPathe - Nuvo Research - Pain Therapeutics - ProStrakan - Purdue Pharma - Sanofi - Scilex Pharmaceuticals - Therapeutic Discovery Corporation - Transdermal Delivery Solutions - UCB - Xel Pharmaceuticals - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/s8...ransdermal
ENDP: 57.64 (+0.52), ZSAN: 2.36 (-0.06), IMNP: 0.70 (+0.04), DRRX: 2.08 (+0.05), AGN: 301.88 (-0.19), CORI: 7.15 (-0.12), JNJ: 101.57 (-0.11), ANIP: 41.96 (-0.65), ATRS: 1.29 (+0.03), PTIE: 1.86 (unch), IMMY: 7.12 (+0.02), NVS: 84.64 (+0.12)

Antares Pharma Announces Enrollment Complete in Quickshot(R) Supplemental Safety Study QST-15-005
GlobeNewswire - Tue Nov 03, 6:00AM CST
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that enrollment has been completed in a dose-blinded, multiple-dose, concentration controlled 26-week safety and pharmacokinetic study of QuickShot Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005 includes a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. The study is being conducted to help ensure that we satisfy the U.S. Food and Drug Administration's recommendation that we have a safety database of approximately 350 subjects exposed to QS T in total with approximately 200 subjects exposed for six months and approximately 100 subjects exposed for a year.
ATRS: 1.29 (+0.03)

STERIS Tops Q2 Earnings, Misses Revenues; Keeps '15 View
Zacks Equity Research - Zacks Investment Research - Mon Nov 02, 8:50AM CST
STERIS (STE) ended the second quarter of fiscal 2016 on a mixed note. Currently, we look forward to the proposed combination of STERIS and Synergy Health, which management expects to close on Nov 2, 2015
IVC: 18.03 (-0.20), ALGN: 64.65 (-0.44), STE: 72.36 (+0.01), ATRS: 1.29 (+0.03)

Antares Pharma Announces Update to Quickshot Testosterone Clinical Program
GlobeNewswire - Fri Oct 30, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the last patient has completed treatment in the dose-blinded, multiple-dose 52 week Phase 3 study to evaluate the efficacy and safety of QuickShot Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism.
ATRS: 1.29 (+0.03)

Antares Pharma to Host Third Quarter 2015 Operating and Financial Results Conference Call
GlobeNewswire - Wed Oct 28, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its third quarter 2015 financial results and recent operating progress before the market opens on Thursday November 5, 2015, and host a webcast and conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Eamonn P. Hobbs, President and Chief Executive Officer, will host the call.
ATRS: 1.29 (+0.03)

Merit Medical Systems (MMSI) Jumps: Stock Gains 7.7%
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 7:00AM CDT
Merit Medical Systems (MMSI) was a big mover last session, with shares rising roughly 8% on the day.
ATRS: 1.29 (+0.03), MMSI: 18.36 (-0.12)

LabCorp Q3 Earnings in Line, Revenues Strong; View Revised
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 8:50AM CDT
Laboratory Corporation of America Holdings (LH) reported solid third quarter 2015 with adjusted earnings per share (EPS) of $2.07, up 15% from the year-ago quarter.
VWR: 26.16 (-0.05), PDCO: 43.57 (-0.19), LH: 120.13 (-1.04), ATRS: 1.29 (+0.03)

Align Technology (ALGN) Jumps: Stock Moves 11.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 7:00AM CDT
Align Technology Inc. (ALGN) was a big mover last session with its shares rising nearly 12% on the day.
ALGN: 64.65 (-0.44), ATRS: 1.29 (+0.03)

Align Technology Q3 Earnings in Line, Revenues Strong
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:05AM CDT
Align Technology 9ALGN) delivered mixed third quarter of 2015 with the top line exceeding the Zacks Consensus Estimate, and the bottom line meeting the same.
VWR: 26.16 (-0.05), ALGN: 64.65 (-0.44), PDCO: 43.57 (-0.19), ATRS: 1.29 (+0.03)

CONMED Lags Q3 Earnings & Sales, View Cut, Stock Down
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 11:10AM CDT
CONMED reported dismal third-quarter 2015 results, missing the Zacks Consensus Estimates on both lines.
VWR: 26.16 (-0.05), CNMD: 40.98 (-0.09), PDCO: 43.57 (-0.19), ATRS: 1.29 (+0.03)

Align Technology (ALGN) in Focus: Stock Rises 7.4%
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 7:00AM CDT
Align Technology (ALGN) was a big mover last session, with shares rising over 7% on the day.
ALGN: 64.65 (-0.44), ATRS: 1.29 (+0.03)

New Strong Buy Stocks for October 12th
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BERY: 35.55 (-0.47), AAC: 23.15 (-0.23), AMGN: 155.11 (-0.04), ATRS: 1.29 (+0.03), ATAX: 5.15 (-0.06)

Antares Pharma Announces Publication of QuickShot(R) Testosterone Data in Prestigious Health Journal
GlobeNewswire - Mon Sep 28, 6:00AM CDT
- Results of the study showed rapid restoration and consistent maintenance of steady blood levels was achieved with once-weekly subcutaneous administration of testosterone using the QuickShot auto injector -
ATRS: 1.29 (+0.03)

Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Dec 09, 9:47PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being sold by Accelerate Diagnostics. The gross proceeds to Accelerate Diagnostics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $95.0 million. The offering is expected to close on or about December 15, 2015, subject to customary closing conditions. In addition, Accelerate Diagnostics has granted the underwriters of the offering a 30-day option to purchase up to an additional 838,235 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
AXDX: 21.92 (+0.49)

Accelerate Diagnostics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Dec 08, 3:01PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $12 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
AXDX: 21.92 (+0.49)

Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance
GlobeNewswire - Wed Dec 02, 4:30AM CST
Accelerate Diagnostics, Inc. announced positive findings from a multicenter pilot study to evaluate external performance of its ID/AST System and Blood Culture Assay Kit. Based on the results of the study, the company also announced the initiation of its clinical trial for submission to the U.S. Food and Drug Administration.
AXDX: 21.92 (+0.49)

Accelerate Diagnostics to Present at the 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015
GlobeNewswire - Tue Dec 01, 4:37PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Piper Jaffray Healthcare Conference in New York City, NY on Wednesday, December 2nd at 12:30 PM ET.
AXDX: 21.92 (+0.49)

5 Stocks Insiders Love Right Now
at The Street - Wed Nov 11, 11:33AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
QSR: 35.05 (-0.54), AXDX: 21.92 (+0.49), SGEN: 39.61 (-0.96), LNG: 40.55 (-0.74), HWAY: 12.30 (-0.18)

Multiple Insiders of Accelerate Diagnostics, Inc. (AXDX)-NasdaqCM bought Shares of AXDX
M2 - Fri Nov 06, 8:17AM CST
Multiple Insiders of Accelerate Diagnostics, Inc. (AXDX)-NasdaqCM bought 52,837 shares of AXDX from the open market on 2015-11-05. The stock was up 4.38% after the InsiderCow.com report.
AXDX: 21.92 (+0.49)

The World Market for Molecular Diagnostics 2015
M2 - Mon Oct 19, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm2bt7/the_world_market) has announced the addition of the "The World Market for Molecular Diagnostics, 6th Edition" report to their offering. Molecular tests are used in just about every facet of laboratory medicine: infectious diseases, inherited diseases, coagulation, transplant medicine, prenatal and postnatal screening and cancer. The World Market for Molecular Diagnostics, 6th Edition, provides authoritative and complete analysis of the molecular testing industry. In this report, exclusive market sizing and forecasts are provided for the following diagnostic segments: - Cancer Markers & PGx - Histology (In situ hybridization, HPV) - Microbiology/Virology (HAI; HIV; Hepatitis; GC/Chlamydia; Respiratory; Organism ID; Mycobacteria, TB; Others) - Blood Screening - Coagulation & PGx - Prenatal Testing - Inherited Diseases Testing - Tissue Typing - Organ Transplant Testing (HLA Typing) - Circulating Tumor Cells (CTCs) - Clinical Sequencing - Flow Cytometry The amount of activity over the last few years is short of phenomenal with a continuous stream of new platforms, tests and quality control materials for test standardization coming to market. There is intense competition but also opportunities for entrants in some areas. Comprehensive Coverage of the Molecular Diagnostics Industry Molecular diagnostics is one of the fastest growth segments in clinical diagnostics, and for the past five years there's been a considerable rate of growth in the number of assays introduced. Moreover, growth of this segment is fuelled by rising incidence of chronic disorders, an increasing geriatric population and adoption of personalized medicines. This report not only contains current market data for business planning, it goes beyond the numbers to fully assess what is going on in the market and why. Since the last edition of this report, a lot has changed, and a lot has stayed the same. As part of its coverage, the report includes the following: - Over 1,000 Pages of Detailed Market Coverage - Over 70 Tables and Figures Makes Market Analysis More Accessible - Current Market Size and Forecast 2014-2019 for Several Specific Molecular IVD Segments - Exome Sequencing, Metabolic Profiling, Hospital Acquired Infections, LDTs, Information Technology, - Status of China and Emerging Markets and Other Trends - Infectious Disease Molecular Sales by Disease - Over 190 Profiles of Molecular Diagnostic Competitors - Recent Mergers and Acquisitions - Revenues of Test Service Companies - Geographic Breakout of the Molecular Diagnostics Market by Region - Sample Preparation Trends - Breakout of Molecular Histology/Cytology Market - Mergers, Partnerships, Distribution Agreements in Molecular IVD Key Topics Covered: 1. Executive Summary 2. Introduction 3. Delivering Molecular Tests To The Clinic 4. Sequencing - How Far Can We Go? 5. Market Analysis: World Markets 6. The Market For Blood Markers In Cancer 7. The Market For Molecular Assays In Hematology: Cell-Based Molecular Tests 8. The Market For Molecular Assays In Coagulation 9. Histology And Cytology 10. Microbiology And Virology 11. The Market For Molecular Assays In Blood Transfusion Medicine 12. The Market For Molecular Assays In Organ Transplant Management 13. The Market For Molecular Assays In Prenatal And Newborn Screening 14. The Market For Molecular Assays For Inherited Diseases 15. Conclusions And Strategic Implications 16. Major Vendors And Companies To Watch 17. Company Profiles: The Top Tier 18. Company Profiles: Major Molecular Companies 19. Company Profiles: Participants 20. Company Profiles: Great Expectations 21. Company Profiles: Newcomers 22. Company Profiles: Test Service Providers 23. Company Profiles: Point Of Care Test Specialists 24. Company Profiles: Sample Preparation 25. Company Profiles: Information Technology Specialists 26. Company Profiles: Histopathology Specialists 27. Company Profiles: Microbiology Specialists 28. Company Profiles: Blood Bank Specialists 29. Company Profiles: Prenatal Test Service Providers 30. Company Profiles: Ctc & Liquid Biopsy Test Providers Companies Mentioned - Partial List - 23andMe - Abbott Diagnostics - Accelerate Diagnostics, Inc. - Adaptive Biotechnologies Corporation - Advaita Bioinformatics - Advanced Biological Laboratories, S.A. (ABL) - Advanced Cell Diagnostics (ACD) - AdvanDx, Inc. - Affymetrix Inc. - Agendia BV - Agilent Technologies - Alere Inc. - AltheaDx Diagnostics, Inc. - altona Diagnostics - Ambry Genetics - Amoy Diagnostics Co. Ltd. - Angle plc - Aperiomics - ApoCell, Inc. - Apple Inc. - Applied Spectral Imaging Inc. (ASI) - Ariosa Diagnostics, Inc. - ARUP Laboratories - Assurex Health - Asuragen Inc. - Athena Diagnostics - Atlas Genetics Ltd. - AutoGenomics Inc. For more information visit http://www.researchandmarkets.com/research/hm...rld_market
AGMX: (), AXDX: 21.92 (+0.49), A: 40.09 (-0.10), ALR: 38.97 (+0.09), AAPL: 110.84 (-2.34), AFFX: 9.24 (+0.10), ATHN: 158.32 (-0.99)

Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015
GlobeNewswire - Wed Aug 05, 4:30AM CDT
Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 13th at 8:00AM ET.
AXDX: 21.92 (+0.49)

4 Unusual-Volume Stocks to Trade for Breakouts
at The Street - Mon Jul 20, 1:06PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
GPRO: 16.81 (-2.34), AXDX: 21.92 (+0.49), SCTY: 37.60 (+0.56), JAH: 54.69 (+2.01)

Supervisors Approve Expansion Lease for Accelerate Diagnostics
GlobeNewswire - Thu Jul 09, 12:04PM CDT
The Pima County Board of Supervisors July 7 voted unanimously to approve a lease for an expansion of Accelerate Diagnostics (Nasdaq:AXDX) at the county's Abrams Public Health Center, 3950 S. Country Club Road.
AXDX: 21.92 (+0.49)

FDA clears upstart Theranos' test system
Seeking Alpha - at Seeking Alpha - Thu Jul 02, 3:07PM CDT

ABT: 44.36 (unch), AXDX: 21.92 (+0.49), BIO: 134.35 (-1.01), CBMX: 0.71 (unch), CPHD: 30.66 (+0.31), QDEL: 21.39 (-0.41), TRIB: 11.29 (-0.16), QGEN: 25.87 (+0.30), CEMI: 5.07 (+0.01)

Accelerate Diagnostics Achieves CE-IVD Milestone for ID/AST System and ID/AST Blood Culture Assay
GlobeNewswire - Tue Jun 30, 10:58PM CDT
Accelerate Diagnostics, Inc., announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. The Accelerate ID/AST System is a diagnostic platform providing rapid identification and antimicrobial susceptibility testing of serious infections.
AXDX: 21.92 (+0.49)

3 Small-Cap Biotech Stocks That Are Challenging the Status Quo
ACCESSWIRE - Mon Jun 29, 8:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been top performers so far this year, with the PowerShares S&P SmallCap Healthcare ETF (NASDAQ: PSCH) returning 25%, which is 5x better than the SPDR S&P 500 ETF's (NYSE: SPY) 5% return. Investors may want to consider adding exposure to this asset class given its outperformance and lower correlation with the overall U.S. equity market.
SPY: 200.93 (-0.95), PSCH: 69.87 (-0.03), AXDX: 21.92 (+0.49)

Why You Should Buy T2 Biosystems And Run Far Far Away From Accelerate Diagnostics
JKenser - at Seeking Alpha - Wed Jun 10, 10:44AM CDT

AXDX: 21.92 (+0.49), TTOO: 9.50 (-0.07)

Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019
M2 - Tue Jun 02, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkw4fq/molecular) has announced the addition of the "Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019" report to their offering. "Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help understand test pricing in detail. See lists of all current FDA Approved Molecular Diagnostic Tests. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges. Trends: - Personalized medicine - Pharmacogenomics - Pathogen evolution - Next generation sequencing - Emergence of new economies with large markets - Greater understanding of the role of genetic material in Disease and Health Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Report Buyers have access to Price and Volume Data for the following individual tests: - Influenza - Tuberculosis - HIV - HBV - HCV - HPV - MRSA - VRSE - Chlamydia/gonorrhea - Prenatal - Blood Screening Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary Appendices I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint II. FDA Approved Human Genetic Tests III. FDA Approved Microbial Tests III. FDA Approved Pharmacogenomics Tests Companies Mentioned: 30 of the 300 companies featured - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - Abbott Diagnostics - Abcam - AbVitro - Accelerate Diagnostics - Acibadem Labmed Laboratory - ACM Medical Laboratory - ACT Genomics - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - AITbiotech - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum - American Pathology Partners, Inc. For more information visit http://www.researchandmarkets.com/research/nkw4fq/molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AXDX: 21.92 (+0.49), ALR: 38.97 (+0.09)

Rosen Law Firm Reminds Accelerate Diagnostics, Inc. Investors of the Important May 18, 2015 Deadline In the Class Action Filed by the Firm - AXDX
GlobeNewswire - Sat May 16, 2:57PM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, reminds purchasers of Accelerate Diagnostics, Inc. (Nasdaq:AXDX) securities from March 7, 2014 through February 17, 2015 of the important May 18, 2015 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Accelerate Diagnostics investors under the federal securities laws.
AXDX: 21.92 (+0.49)

DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Accelerate Diagnostics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - AXDX
GlobeNewswire - Wed May 13, 4:33PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Accelerate Diagnostics, Inc. ("Accelerate Diagnostics" or the "Company" (Nasdaq:AXDX) securities during the period between March 7, 2014 and February 17, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until May 18, 2015 to seek appointment as lead plaintiff.
AXDX: 21.92 (+0.49)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Accelerate Diagnostics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 18, 2015 -- AXDX
GlobeNewswire - Wed May 13, 11:00AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
AXDX: 21.92 (+0.49)

May 18 Deadline in Lawsuit for Investors in Accelerate Diagnostics Inc (NASDAQ:AXDX) Shares Announced by Shareholders Foundation
GlobeNewswire - Wed May 13, 8:55AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of shares of Accelerate Diagnostics Inc (Nasdaq:AXDX) over alleged Violations of Federal Securities Laws by Accelerate Diagnostics Inc in connection with certain allegedly false and misleading statements.
AXDX: 21.92 (+0.49)

ACCELERATE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Accelerate Diagnostics, Inc. (AXDX) to Contact the Firm Ahead of Imminent Lead Plaintiff Deadline
GlobeNewswire - Sat May 09, 2:00PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Accelerate Diagnostics, Inc. ("Accelerate" or the "Company" (Nasdaq:AXDX) of the May 21, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Accelerate and certain executives of the Company.
AXDX: 21.92 (+0.49)